We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy . Corbus Pharmaceuticals Holdings, Inc. is among the best biotech stocks.
TheFly reported on April 7 that Mizuho raised its price target on CRBP from $39 to $40 while maintaining an Outperform rating. The firm updated its valuation model following the company's fourth quarter results. The corporation is expected to deliver three clinical data readouts during 2026, which the firm views as key upcoming catalysts. Mizuho also noted that the stock is currently trading near the company's cash position, suggesting limited downside and an attractive risk-reward profile ahead of multiple potential data-driven events.
Additionally, on April 7, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced it has reached broad alignment with the U.S. FDA on the registration strategy for CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate being developed for head and neck squamous cell carcinoma and cervical cancer.
The planned registrational approach includes separate randomized controlled studies in each indication comparing CRB-701 to standard chemotherapy regimens, with objective response rate as the basis for potential accelerated approval and overall survival as the confirmatory endpoint for full approval. The company will continue discussions with the FDA to finalize study protocols and statistical analysis plans. In addition, Corbus disclosed a leadership change, with its chief medical officer stepping down effective June 30, 2026.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for inflammatory and fibrotic diseases. It is also expanding into oncology, aiming to create targeted treatments that modulate the immune system and improve patient outcomes.
While we acknowledge the potential of CRBP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts .
Disclosure: None. Follow Insider Monkey on Google News .
